Kami Maddocks, MD, The Ohio State University

Articles by Kami Maddocks, MD, The Ohio State University

Evolving Therapies in R/R DLBCL: Concluding Remarks

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 26th 2021

R/R DLBCL: A Glance at Using Novel Therapies Moving Forward

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 26th 2021

R/R DLBCL: Novel Therapies in the Pipeline

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 26th 2021

Treating Primary Refractory DLBCL

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 19th 2021

Bridging Therapy in R/R DLBCL

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 19th 2021

R/R DLBCL: Transplants in the Era of CAR-T

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 12th 2021

CAR T for R/R DLBCL: Improving Access and Utilization

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 12th 2021

CAR T for R/R DLBCL: Safety/Tolerability

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 5th 2021

Understanding the CAR-T Process: Collection Through Infusion

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 5th 2021

Treating R/R DLBCL With CAR-T: Current Barriers

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 26th 2021

CAR-T Treatment Options for R/R DLBCL

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 26th 2021

CAR T-Cell Therapy for R/R DLBCL

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 19th 2021

Novel Therapies for R/R DLBCL

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 19th 2021

R/R DLBCL: Treating With Tafasitamab-Lenalidomide

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 12th 2021

Tafasitamab Combined With Lenalidomide in R/R DLBCL

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 12th 2021

R/R DLBCL: Second-Line Treatment Options

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 5th 2021

DLBCL: Treating Patients Following Relapse on Frontline Therapy

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 5th 2021

DLBCL: Treatment Considerations for Challenging Populations

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

January 29th 2021

DLBCL: Circumstances for Deviating Away From R-CHOP

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

January 29th 2021

Latest Updated Articles

Treating R/R DLBCL With CAR-T: Current Barriers
February 26th 2021
CAR T-Cell Therapy for R/R DLBCL
February 19th 2021
R/R DLBCL: Transplants in the Era of CAR-T
March 12th 2021
R/R DLBCL: Treating With Tafasitamab-Lenalidomide
February 12th 2021
Evolving Therapies in R/R DLBCL: Concluding Remarks
March 26th 2021
Bridging Therapy in R/R DLBCL
March 19th 2021

Trending on OncLive

FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer

FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer

VIR-5500 Receives FDA Fast Track Designation in mCRPC

September Roundup of FDA Approvals in Oncology: 8 Decisions to Know

Individualized Neoantigen Vaccine Elicits Durable T-Cell Responses in Resected HPV– HNSCC